News

Filter by:

Showing 12 of 579 Results

April 24, 2024 General News

Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2024

April 22, 2024 General News

Acadia Pharmaceuticals Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada

April 19, 2024 General News

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 17, 2024 General News

Acadia Pharmaceuticals Presents New DAYBUE™ (trofinetide) Clinical Data at the 2024 American Academy of Neurology (AAN) Annual Meeting

April 2, 2024 General News

Acadia Appoints Elizabeth H. Z. Thompson, Ph.D. as Executive Vice President, Head of Research and Development

April 1, 2024 General News

Acadia Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference

March 15, 2024 General News

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 13, 2024 General News

Acadia Pharmaceuticals to Participate in the UBS Virtual CNS Day

March 11, 2024 Earnings News

Acadia Pharmaceuticals Announces Top-Line Results from Phase 3 ADVANCE-2 Trial of Pimavanserin in Negative Symptoms of Schizophrenia

February 29, 2024 General News

Acadia Pharmaceuticals to Participate in TD Cowen’s 44th Annual Health Care Conference on March 6, 2024

February 27, 2024 Earnings News

Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operating Overview

February 21, 2024 General News

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Load More Results